{"preliminary_commentary":{"by_channel":{"youtube":46,"x_thread":40,"podcast":38,"bluesky_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02504372\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"completely resected stage IB-IIIA non-small-cell lung cancer","name":"KEYNOTE-091","nct_id":"NCT02504372","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-091-nct02504372. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PEARLS","arms":[{"description":"Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["ETOP","European Organisation for Research and Treatment of Cancer - EORTC"],"completion_date":{"date":"2026-01-21","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":1177,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-03-17","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-01-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS)","timeFrame":"Up to approximately 84 months"},{"measure":"DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%","timeFrame":"Up to approximately 84 months"}],"references":[{"citation":"O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S; EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.","pmid":"36108662","type":"DERIVED"}],"start_date":{"date":"2015-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","url":"https://clinicaltrials.gov/study/NCT02504372"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-091-nct02504372"}